(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
07 October 2021 (07.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/198705 A1

(51) International Patent Classification:
A61K 39/12 (2006.01) *A61K 39/00* (2006.01)
A61P 31/14 (2006.01)

(21) International Application Number:
PCT/GB2021/050829

(22) International Filing Date:
01 April 2021 (01.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2004974.8	03 April 2020 (03.04.2020)	GB
16/842,669	07 April 2020 (07.04.2020)	US
2016172.5	12 October 2020 (12.10.2020)	GB

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 16/842,669 (CIP)
Filed on 07 April 2020 (07.04.2020)

(71) Applicant: **PEPTC VACCINES LIMITED** [GB/GB]; 85 Great Portland Street, First Floor, London Greater London W1W 7LT (GB).

(72) Inventors: **CSISZOVSZKI, Zsolt**; Bikszádi u. 12/A, 4/9, 1119 Budapest (HU). **LORINCZ, Orsolya**; Attila u. 27, fszt/13, 1047 Budapest (HU). **MOLNÁR, Levente**; Kossuth Lajos u. 20, 2363 Felsopakony (HU). **PÁLES, Péter**; Csomafalva u. 5, 1173 Budapest (HU). **PÁNTYA, Katalin**; Platán utca 4, 2310 Szigetszentmiklós (HU). **SOMOGYI, Eszter**; Borgazda u. 3, 8220 Balatonalmádi (HU). **TÓTH, József**; Jakab József utca 15., 5. em. 7, 1138 Budapest (HU). **TOKE, Eniko Rita**; Kossuth Lajos u. 20, 2363 Felsopakony (HU).

(74) Agent: **J A KEMP LLP**; 14 South Square, Gray's Inn, London Greater London WC1R 5JJ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2021/198705 A1

(54) Title: CORONAVIRUS VACCINE

(57) Abstract: The disclosure relates to polypeptides, vaccines and pharmaceutical compositions that find use in the prevention or treatment of Coronaviridae or SARS-CoV-2 infection. The disclosure also relates to methods of treating or preventing Coronaviridae or SARS-CoV-2 infection in a subject. The polypeptides and vaccines comprise B cell epitopes and cytotoxic and helper T cell epitopes that are immunogenic in a high percentage of subjects in the human population.